Michael Sinclair, MD
Family Medicine · Loxahatchee, FLNPI 1043200181
Payments from drug & device makers
Across 439 payments — averaging $37.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$4K
- Pfizer$4K
- AstraZeneca$2K
- Bayer$847
- Novo Nordisk$835
- Amgen$798
- plus $4K from 34 others
What the payments were for
- Consulting fees$2,10013%
- Speaking & faculty fees$2,20014%
- Travel & lodging$2,94718%
- Food & beverage$8,99155%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 19 | $4,399 |
| Pfizer | 32 | $4,100 |
| AstraZeneca | 90 | $1,599 |
| Bayer | 37 | $847 |
| Novo Nordisk | 35 | $835 |
| Amgen(2 entities) | 39 | $798 |
| Lilly USA, LLC | 34 | $572 |
| GSK | 25 | $441 |
| AbbVie(2 entities) | 19 | $360 |
| Abbott | 13 | $342 |
| Novartis | 14 | $295 |
| Amarin Pharma, Inc. | 13 | $194 |
| Boehringer Ingelheim | 4 | $167 |
| Sanofi-aventis U.S. LLC | 3 | $163 |
| Arbor Pharmaceuticals, Inc. | 6 | $121 |
| Teva Pharmaceuticals USA, Inc. | 7 | $109 |
| Idorsia Pharmaceuticals US Inc | 5 | $100 |
| Exact Sciences | 3 | $79 |
| Tolmar, Inc. | 4 | $76 |
| Antares Pharma, Inc. | 4 | $68 |
| Merck | 4 | $62 |
| Organogenesis Inc. | 2 | $61 |
| Boston Scientific | 3 | $47 |
| Upsher-smith Laboratories LLC | 2 | $47 |
| Eisai Inc. | 3 | $42 |
| Reprise Biomedical, Inc. | 1 | $41 |
| Dexcom, Inc. | 2 | $40 |
| LEO Pharma Inc. | 2 | $37 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Merz North America, Inc. | 1 | $30 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Medtronic | 1 | $18 |
| Promius Pharma LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Integra Lifesciences Corporation | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Virtus Pharmaceuticals LLC | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,283 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 116 | $122,368 |
| FarxigaDapagliflozin Propanediol | 89 | $93,648 |
| OzempicSemaglutide | 53 | $68,628 |
| JardianceEmpagliflozin | 41 | $52,608 |
| EliquisApixaban | 43 | $46,148 |
| JanuviaSitagliptin Phosphate | 21 | $24,561 |
| Repatha SureclickEvolocumab | 25 | $19,746 |
| KerendiaFinerenone | 22 | $17,512 |
| Rosuvastatin Calcium | 791 | $11,846 |
| Ezetimibe | 458 | $11,742 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $11,471 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,528 |
| VascepaIcosapent Ethyl | 13 | $8,288 |
| Telmisartan | 165 | $5,741 |
| Olmesartan Medoxomil | 136 | $3,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $572 | $122,368116 claims |
| AstraZenecaFarxiga | $1,599 | $93,64889 claims |
| Novo NordiskOzempic | $835 | $68,62853 claims |
| Boehringer IngelheimJardiance | $167 | $52,60841 claims |
| PfizerEliquis | $4,100 | $46,14843 claims |
| MerckJanuvia | $62 | $24,56121 claims |
| BayerKerendia | $847 | $17,51222 claims |
| GSKTrelegy Ellipta | $441 | $10,52811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Loxahatchee
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.